ProPhase Labs, Inc. Amortization of Deferred Loan Origination Fees, Net
ProPhase Labs, Inc. (PRPH) reported Amortization of Deferred Loan Origination Fees, Net of -$10.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfDeferredLoanOriginationFeesNet · last filed 2019-03-26
- ProPhase Labs, Inc. amortization of deferred loan origination fees, net for the quarter ending 2017-12-31 was $0.00.
- ProPhase Labs, Inc. amortization of deferred loan origination fees, net for the quarter ending 2017-09-30 was $0.00.
- ProPhase Labs, Inc. amortization of deferred loan origination fees, net for the quarter ending 2017-06-30 was $0.00.
- ProPhase Labs, Inc. amortization of deferred loan origination fees, net for the quarter ending 2017-03-31 was -$10.00K.
- ProPhase Labs, Inc. amortization of deferred loan origination fees, net for fiscal 2017 was -$10.00K.
- ProPhase Labs, Inc. amortization of deferred loan origination fees, net for fiscal 2016 was -$24.00K.
| Period end | Amortization of Deferred Loan Origination Fees, Net 3 month | Amortization of Deferred Loan Origination Fees, Net 3 month as first filed | Amortization of Deferred Loan Origination Fees, Net 6 month | Amortization of Deferred Loan Origination Fees, Net 9 month | Amortization of Deferred Loan Origination Fees, Net 12 month |
|---|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2019-03-26 | $0.00 derived: sum of 2 quarters · filed 2019-03-26 | $0.00 derived: sum of 3 quarters · filed 2019-03-26 | -$10.00K 10-K · filed 2019-03-26 | |
| 2017-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-08-20 | $0.00 derived: sum of 2 quarters · filed 2018-08-20 | -$10.00K 10-Q/A · filed 2018-08-20 | -$16.00K derived: sum of 4 quarters · filed 2018-08-20 | |
| 2017-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-08-20 | -$10.00K 10-Q/A · filed 2018-08-20 | -$16.00K derived: sum of 3 quarters · filed 2018-08-20 | -$22.00K derived: sum of 4 quarters · filed 2018-08-20 | |
| 2017-03-31 | -$10.00K 10-Q/A · filed 2018-08-20 | -$16.00K derived: sum of 2 quarters · filed 2018-08-20 | -$22.00K derived: sum of 3 quarters · filed 2018-08-20 | -$28.00K derived: sum of 4 quarters · filed 2018-08-20 | |
| 2016-12-31 | -$6.00K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2018-08-20 | -$12.00K derived: sum of 2 quarters · filed 2018-08-20 | -$18.00K derived: sum of 3 quarters · filed 2018-08-20 | -$24.00K 10-K/A · filed 2018-08-20 | |
| 2016-09-30 | -$6.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-08-20 | -$12.00K derived: sum of 2 quarters · filed 2018-08-20 | -$18.00K 10-Q/A · filed 2018-08-20 | ||
| 2016-06-30 | -$6.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-08-20 | -$12.00K 10-Q/A · filed 2018-08-20 | |||
| 2016-03-31 | -$6.00K 10-Q/A · filed 2018-08-20 | $6.00K 10-Q · filed 2016-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |